Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of
the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain …

The delivery of immunomodulators directly into the tumor potentially harnesses the existing
antigen, tumor-specific infiltrating lymphocytes, and antigen presenting cells. This can confer …

Background Accumulating evidence has shown that different immunotherapies for ovarian
cancer might overcome barriers to resistance to standard chemotherapy. The vaccine …

Modulating the tumor microenvironment to promote an effective immune response is critical
in managing any type of tumor. Melanoma is an aggressive skin cancer and the incidence …

Background Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen
which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase …

Simple Summary Immunotherapy using immune checkpoint inhibitors is now the first line
standard of care for advanced melanoma but> 50% of patients still do not benefit. Using a …

Our laboratory has previously demonstrated that melanoma draining lymph node (MDLN)
samples from stage III patients contained both CD4+ and CD8+ T cells that can be readily …

Представлен анализ данных литературы о диагностической, прогностической и
терапевтической роли экспрессии гена PRAME при онкологических заболеваниях …

Антиген PRAME, представляющий собой значимую мишень для моноклональных
антител, является онкоспецифическим маркером, который активен на всех стадиях …

Malignant melanoma is an aggressive cancer with increasing incidence, frequent metastasis
and poor prognosis. It is also an immunogenic cancer and clinical and experimental data …